<p>馬薩諸塞州劍橋和丹麥哥本哈根，2026 年 4 月 30 日（環球新聞通訊社）—— Hemab Therapeutics Holdings, Inc.（納斯達克：COAG），一家臨牀階段的生物技術公司，正在開發重新構想血液凝固障礙治療的療法，以維持生命和人類的韌性，今天宣佈其首次公開募股的定價，發行 16,750,000 股普通股，公開發行價格為每股 18.00 美元。此外，Hemab 已向承銷商授予 30 天的選擇權，以公開發行價格購買最多 2,512,500 股普通股，扣除承銷折扣和佣金。所有普通股均由 Hemab 提供。</p>
<p>Hemab 的普通股預計將於 2026 年 5 月 1 日星期五在納斯達克全球精選市場開始交易，股票代碼為 “COAG”。在扣除 Hemab 應支付的承銷折扣和佣金及其他發行費用之前，預計此次發行的總收益約為 3.015 億美元，不包括承銷商選擇權的任何行使。此次發行預計將在 2026 年 5 月 4 日左右完成，具體情況取決於慣例的交割條件。</p>
<p>高盛公司、傑弗裏金融和 Evercore ISI 擔任此次發行的聯合賬簿管理人。Wedbush PacGrow 擔任此次發行的首席管理人。</p>
<p>與此次發行相關的證券註冊聲明已向證券交易委員會提交，並於 2026 年 4 月 30 日獲得有效。此次發行僅通過招股説明書進行。最終招股説明書的副本在可用時可從高盛公司索取，注意：招股説明書部門，地址：200 West Street, New York, NY 10282，電話：1-866-471-2526，或通過電子郵件聯繫：prospectus-ny@ny.email.gs.com；傑弗裏金融，注意：股權承銷招股説明書部門，地址：520 Madison Avenue, New York, NY 10022，電話：(877) 821-7388，或通過電子郵件聯繫：Prospectus_Department@Jefferies.com；或 Evercore Group L.L.C.，注意：股權資本市場，地址：55 East 52nd Street, New York, NY 10055，電話：(888) 474-0200，或通過電子郵件聯繫：ecm.prospectus@evercore.com。</p>
<p>本新聞稿不構成出售這些證券的要約，也不構成購買這些證券的要約邀請，亦不應在任何州或司法管轄區內進行這些證券的要約、邀請或銷售，若在任何此類州或司法管轄區內的證券法下未進行註冊或資格審查，則此類要約、邀請或銷售將是非法的。</p>
<p><strong>關於 Hemab Therapeutics</strong></p>
<p>Hemab Therapeutics Holdings, Inc.是一家臨牀階段的生物技術公司，正在開發重新構想血液凝固障礙治療的療法，以維持生命和人類的韌性。Hemab 的使命是為全球數百萬患有嚴重出血和血栓性疾病的患者發現、開發和商業化創新療法。Hemab 正在建立一系列創新療法，旨在解決凝固障礙治療中的關鍵空白，包括 sutacimig（HMB-001），一種正在臨牀開發中的雙特異性抗體，用於 Glanzmann 血小板無力症和 VII 因子缺乏症的預防性治療，以及 HMB-002，一種正在臨牀開發中的單價抗體，用於 Von Willebrand 病的預防性治療。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿中關於未來期望、計劃和前景的聲明，以及關於非歷史事實的其他聲明，可能構成 “前瞻性聲明”。這些聲明包括但不限於與首次公開募股的交割日期、在納斯達克全球精選市場的交易開始以及預計的發行總收益相關的聲明。詞語 “預期”、“相信”、“繼續”、“可能”、“估計”、“期望”、“打算”、“可能”、“計劃”、“潛在”、“預測”、“項目”、“應該”、“目標”、“將”、“會” 等類似表達旨在識別前瞻性聲明，儘管並非所有前瞻性聲明都包含這些或類似的識別詞。實際結果可能因各種重要因素而與這些前瞻性聲明所指示的結果有重大差異，包括：與市場條件相關的不確定性以及首次公開募股是否按預期條款完成的其他因素，以及在向證券交易委員會提交的有效註冊聲明的初步招股説明書的 “風險因素” 部分中討論的其他因素。本新聞稿中包含的任何前瞻性聲明均基於 Hemab 管理團隊當前的期望，僅在本日期有效，Hemab 特別聲明不承擔更新任何前瞻性聲明的義務，無論是由於新信息、未來事件還是其他原因，法律要求的除外。</p>
<p><strong>媒體：</strong></p>
<p>德爾菲德</p>
<p>佩格·魯斯科尼</p>
<p>peg.rusconi@deerfieldgroup.com</p>
<p><strong>投資者：</strong></p>
<p>Hemab Therapeutics</p>
<p>馬茲·貝恩德特</p>
<p>investors@hemab.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1URTNNU00zTlRjM05qYzNJekl6TVRBeU56RT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1URTNNU00zTlRjM05qYzNJekl6TVRBeU56RT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODA2NTAwNWItYjg4Mi00M2QxLTk5MGMtYWQwYjJlMGZiNzYzLTEzMjE4MjEtMjAyNi0wNC0zMC1lbg==/tiny/Hemab-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODA2NTAwNWItYjg4Mi00M2QxLTk5MGMtYWQwYjJlMGZiNzYzLTEzMjE4MjEtMjAyNi0wNC0zMC1lbg==/tiny/Hemab-Therapeutics-Inc-.png"/></p>

高盛

<p>Hemab Therapeutics Holdings, Inc. 將其首次公開募股（IPO）定價為每股 18.00 美元，提供 16,750,000 股，並給予承銷商購買額外 2,512,500 股的選擇權。此次 IPO 預計將籌集約 3.015 億美元，並將於 2026 年 5 月 1 日在納斯達克以 “COAG” 為股票代碼開始交易。此次發行預計將在 2026 年 5 月 4 日左右結束，具體情況需遵循慣例條件。高盛、傑富瑞和 Evercore ISI 是此次發行的聯合賬簿管理人</p>

<p>CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the pricing of its initial public offering of 16,750,000 shares of its common stock at a public offering price of $18.00 per share. In addition, Hemab has granted the underwriters a 30-day option to purchase up to an additional 2,512,500 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Hemab.</p>
<div class="lb-trans"><p>馬薩諸塞州劍橋和丹麥哥本哈根，2026 年 4 月 30 日（環球新聞通訊社）—— Hemab Therapeutics Holdings, Inc.（納斯達克：COAG），一家臨牀階段的生物技術公司，正在開發重新構想血液凝固障礙治療的療法，以維持生命和人類的韌性，今天宣佈其首次公開募股的定價，發行 16,750,000 股普通股，公開發行價格為每股 18.00 美元。此外，Hemab 已向承銷商授予 30 天的選擇權，以公開發行價格購買最多 2,512,500 股普通股，扣除承銷折扣和佣金。所有普通股均由 Hemab 提供。</p>
</div><p>Hemab’s common stock is expected to begin trading on the Nasdaq Global Select Market on Friday, May 1, 2026 under the ticker symbol “COAG.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Hemab, are expected to be approximately $301.5 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about May 4, 2026, subject to customary closing conditions.</p>
<div class="lb-trans"><p>Hemab 的普通股預計將於 2026 年 5 月 1 日星期五在納斯達克全球精選市場開始交易，股票代碼為 “COAG”。在扣除 Hemab 應支付的承銷折扣和佣金及其他發行費用之前，預計此次發行的總收益約為 3.015 億美元，不包括承銷商選擇權的任何行使。此次發行預計將在 2026 年 5 月 4 日左右完成，具體情況取決於慣例的交割條件。</p>
</div><p>Goldman Sachs &amp; Co. LLC, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.</p>
<div class="lb-trans"><p>高盛公司、傑弗裏金融和 Evercore ISI 擔任此次發行的聯合賬簿管理人。Wedbush PacGrow 擔任此次發行的首席管理人。</p>
</div><p>A registration statement relating to the securities being sold in the offering has been filed with the Securities and Exchange Commission and was declared effective on April 30, 2026. The offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from Goldman Sachs &amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.</p>
<div class="lb-trans"><p>與此次發行相關的證券註冊聲明已向證券交易委員會提交，並於 2026 年 4 月 30 日獲得有效。此次發行僅通過招股説明書進行。最終招股説明書的副本在可用時可從高盛公司索取，注意：招股説明書部門，地址：200 West Street, New York, NY 10282，電話：1-866-471-2526，或通過電子郵件聯繫：prospectus-ny@ny.email.gs.com；傑弗裏金融，注意：股權承銷招股説明書部門，地址：520 Madison Avenue, New York, NY 10022，電話：(877) 821-7388，或通過電子郵件聯繫：Prospectus_Department@Jefferies.com；或 Evercore Group L.L.C.，注意：股權資本市場，地址：55 East 52nd Street, New York, NY 10055，電話：(888) 474-0200，或通過電子郵件聯繫：ecm.prospectus@evercore.com。</p>
</div><p>This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售這些證券的要約，也不構成購買這些證券的要約邀請，亦不應在任何州或司法管轄區內進行這些證券的要約、邀請或銷售，若在任何此類州或司法管轄區內的證券法下未進行註冊或資格審查，則此類要約、邀請或銷售將是非法的。</p>
</div><p><strong>About Hemab Therapeutics</strong></p>
<div class="lb-trans"><p><strong>關於 Hemab Therapeutics</strong></p>
</div><p>Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.</p>
<div class="lb-trans"><p>Hemab Therapeutics Holdings, Inc.是一家臨牀階段的生物技術公司，正在開發重新構想血液凝固障礙治療的療法，以維持生命和人類的韌性。Hemab 的使命是為全球數百萬患有嚴重出血和血栓性疾病的患者發現、開發和商業化創新療法。Hemab 正在建立一系列創新療法，旨在解決凝固障礙治療中的關鍵空白，包括 sutacimig（HMB-001），一種正在臨牀開發中的雙特異性抗體，用於 Glanzmann 血小板無力症和 VII 因子缺乏症的預防性治療，以及 HMB-002，一種正在臨牀開發中的單價抗體，用於 Von Willebrand 病的預防性治療。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to the closing date of the initial public offering, the commencement of trading on the Nasdaq Global Select Market and the anticipated gross proceeds from the offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms of the offering or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus that forms a part of the effective registration statement filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Hemab’s management team and speak only as of the date hereof, and Hemab specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.</p>
<div class="lb-trans"><p>本新聞稿中關於未來期望、計劃和前景的聲明，以及關於非歷史事實的其他聲明，可能構成 “前瞻性聲明”。這些聲明包括但不限於與首次公開募股的交割日期、在納斯達克全球精選市場的交易開始以及預計的發行總收益相關的聲明。詞語 “預期”、“相信”、“繼續”、“可能”、“估計”、“期望”、“打算”、“可能”、“計劃”、“潛在”、“預測”、“項目”、“應該”、“目標”、“將”、“會” 等類似表達旨在識別前瞻性聲明，儘管並非所有前瞻性聲明都包含這些或類似的識別詞。實際結果可能因各種重要因素而與這些前瞻性聲明所指示的結果有重大差異，包括：與市場條件相關的不確定性以及首次公開募股是否按預期條款完成的其他因素，以及在向證券交易委員會提交的有效註冊聲明的初步招股説明書的 “風險因素” 部分中討論的其他因素。本新聞稿中包含的任何前瞻性聲明均基於 Hemab 管理團隊當前的期望，僅在本日期有效，Hemab 特別聲明不承擔更新任何前瞻性聲明的義務，無論是由於新信息、未來事件還是其他原因，法律要求的除外。</p>
</div><p><strong>Media:</strong></p>
<div class="lb-trans"><p><strong>媒體：</strong></p>
</div><p>Deerfield</p>
<div class="lb-trans"><p>德爾菲德</p>
</div><p>Peg Rusconi</p>
<div class="lb-trans"><p>佩格·魯斯科尼</p>
</div><p>peg.rusconi@deerfieldgroup.com</p>
<div class="lb-trans"><p>peg.rusconi@deerfieldgroup.com</p>
</div><p><strong>Investors:</strong></p>
<div class="lb-trans"><p><strong>投資者：</strong></p>
</div><p>Hemab Therapeutics</p>
<div class="lb-trans"><p>Hemab Therapeutics</p>
</div><p>Mads Behrndt</p>
<div class="lb-trans"><p>馬茲·貝恩德特</p>
</div><p>investors@hemab.com</p>
<div class="lb-trans"><p>investors@hemab.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1URTNNU00zTlRjM05qYzNJekl6TVRBeU56RT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcxMTE3MSM3NTc3Njc3IzIzMTAyNzE="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODA2NTAwNWItYjg4Mi00M2QxLTk5MGMtYWQwYjJlMGZiNzYzLTEzMjE4MjEtMjAyNi0wNC0zMC1lbg==/tiny/Hemab-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ODA2NTAwNWItYjg4Mi00M2QxLTk5MGMtYWQwYjJlMGZiNzYzLTEzMjE4MjEtMjAyNi0wNC0zMC1lbg==/tiny/Hemab-Therapeutics-Inc-.png"/></p>

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering | COAG Stock News

StockTitan

Hemab Therapeutics 宣佈擴大規模的首次公開募股定價 | COAG 股票新聞